Type 1 IGF Receptor Localization in Paediatric Gliomas: Significant Association with WHO Grading and Clinical Outcome

CLÉMENT F EQUAL CONTRIBUTION; CALCAGNO MARIA; GARCIA LOMBARDI MERCEDES; MARTIN A EQUAL CONTRIBUTION; MATHO CECILIA; BREGADÁ IGNACIO; VENARA MARCELA; MAGLIO SILVANA; PENNISI PATRICIA

Hormones and Cancer

Springer

Año: 2018

1868-8497

ABSTRACTBackground: Nuclear localization of insulin-like growth factor receptor type 1 (IGF-1R) has been described as adverse prognostic factor in some cancers. We studied the expression and localization of IGF-1R in paediatric patients with gliomas, its association with World Health Organization (WHO) grading and survival.Methods: We conducted a single cohort, prospective study of paediatric patients with gliomas. Samples were taken at the time of the initial surgery; IGF-1R expression and localization was characterized by immunohistochemistry (IHC), subcellular fractionation and western blotting. Results: 47/53 tumours showed positive staining for IGF-1R by IHC. IGF-1R nuclear labeling was observed in 10/47 cases. IGF-1R staining was mostly non-nuclear in low grade tumours, while IGF-1R nuclear labeling was predominant in high grade gliomas (p=0.0001). Survival was significantly longer in patients with gliomas having non-nuclear IGF-1R localization than in patients with nuclear IGF-1R tumours (p = 0.016). Conclusion: In gliomas, IGF-1R nuclear localization was significantly associated with both high grade tumours and increased risk of death. Based on a prospective design, we provide evidence of a potential usefulness of intracellular localization of IGF-1R as prognostic factor in paediatric patients with gliomas.